Lespessailles Eric
Service de rhumatologie, CHR, Orléans (45).
Presse Med. 2006 Oct;35(10 Pt 2):1565-70. doi: 10.1016/s0755-4982(06)74852-7.
There is no linear relation between changes in bone mineral density (BMD) and reduction in fracture risk with antiresorptive agents. Interpretation of BMD changes at the individual level requires calculating the smallest significant change at each measurement center. BMD measurement is essential before administration of antiresorptive or anabolic agents for prevention or treatment of postmenopausal osteoporosis. Biochemical markers of bone turnover can be monitored after 6 months of treatment. Their interpretation requires careful assessment of their intraindividual variability.
骨矿物质密度（BMD）的变化与抗吸收药物降低骨折风险之间不存在线性关系。在个体层面解释BMD变化需要计算每个测量中心的最小显著变化。在使用抗吸收或促合成药物预防或治疗绝经后骨质疏松症之前，BMD测量至关重要。治疗6个月后可监测骨转换的生化标志物。对它们的解释需要仔细评估其个体内变异性。
